We are a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet medical needs in the treatment of cancer. We aim to disrupt conventional approaches to CAR-T cell therapies with our proprietary technology platforms—FasTCAR and TruUCAR. Our lead FasTCAR-enabled autologous product candidate, GC012F, has achieved multiple […]

We are the No.1 branded e-vapor company in China, capturing 48.0% and 62.6% of the market share of closed-system e-vapor products in terms of retail sales value in 2019 and the nine months ended Sept. 30, 2020, respectively, according to the CIC Report. We deeply engage in the key activities in the e-vapor industry, from […]

iSpecimen is technology-driven company founded to address a critical challenge: how to connect life science researchers who need human for their research, with the billions of biospecimens available (but not easily accessible) in healthcare provider organizations worldwide. Our ground-breaking iSpecimen Marketplace platform was designed to solve this problem and transform the biospecimen procurement process to […]

We intend to focus our search on a target with operations or prospective operations in the technology, financial services, or media sectors, which we refer to as the “new economy sectors”, in Southeast Asia, although we may also explore compelling opportunities in South Asia. We believe that Southeast Asia is entering a new era of […]

While we may pursue acquisitions in any industry or geography, we intend to avoid companies in highly cyclical sectors such as upstream and midstream energy, commodities or real estate. (This blank-check company’s sponsor is an affiliate of Hamilton Lane Advisors, L.L.C., whose managing member is the private equity firm, Hamilton Lane, Inc. (Nasdaq: HLNE).)  (Note: […]

We intend to capitalize on the ability of our management team to identify, acquire and manage a growth-oriented, market leading business. We will look for target companies in Europe and North America. Manfredi Lefebvre d’Ovidio has been our chairman of the board of directors since December 2020. Mr. Lefebvre is chairman of Heritage Group, a diversified conglomerate […]

We intend to initially focus our search on technology-driven, disruptive companies. (Note: Hudson Executive Investment Corp. II upsized its IPO at pricing on Jan. 25, 2021, to 22.5 million units, up from 20 million in the prospectus, at $10 each to raise $225 million.)

We intend to focus our efforts on seeking and completing an initial business combination with a company that has an enterprise value of between $1.0 billion and $3.0 billion. The industry sectors that we intend to target, many of which are undergoing technology-driven transformation, include consumer, food, branded products, e-commerce and retail disruptors and consumerization of healthcare, as well […]

We intend to focus our search for a target business in the energy technology arena targeting industries that require sustainable and innovative solutions to decarbonize in order to meet critical emission reduction objectives. 

We intend to focus our search for a target business in the healthcare sector, with a particular focus on life sciences/biotechnology, healthcare information technology, medical technology and technology-enabled healthcare service sectors. (Note: Biotech Acquisition priced its IPO on Jan. 25, 2021, according to the terms in its prospectus: 20 million units at $10 each to raise $200 […]